微电生理(688351) - 2022 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2022 reached ¥69,999,753.17, representing a 49.76% increase compared to the same period last year[9] - Net profit attributable to shareholders was ¥1,217,588.96, marking a turnaround from a loss in the previous year[9] - Basic earnings per share for Q3 2022 were ¥0.0029, reflecting profit growth driven by increased revenue[12] - Total operating revenue for the first three quarters of 2022 reached ¥191,907,793.27, a 39.7% increase from ¥137,356,717.52 in the same period of 2021[42] - Net profit for the third quarter of 2022 was ¥2,708,185.60, compared to a net loss of ¥5,502,186.98 in the same quarter of 2021[44] - Earnings per share for the third quarter of 2022 were ¥0.0066, recovering from a loss of ¥0.0138 per share in the same quarter of 2021[47] Expenses and Costs - R&D expenses totaled ¥25,768,251.35, accounting for 36.81% of revenue, a decrease of 8.69 percentage points year-on-year[12] - Total operating costs for the first three quarters of 2022 were ¥189,166,794.94, up 28.1% from ¥147,744,552.68 in 2021[42] - Research and development expenses for the first three quarters of 2022 were ¥53,577,900.37, compared to ¥42,840,189.71 in 2021, marking a 25.2% increase[42] Assets and Liabilities - Total assets increased by 165.99% to ¥1,779,072,710.93 compared to the end of the previous year[12] - Total current assets as of September 30, 2022, amounted to CNY 1,603,516,272.33, a significant increase from CNY 508,429,815.85 at the end of 2021, reflecting a growth of approximately 215.5%[33] - Cash and cash equivalents increased to CNY 1,354,608,802.07 from CNY 430,279,216.79, representing a growth of about 214.5%[33] - Total liabilities increased to ¥106,288,967.17 in 2022 from ¥79,212,380.32 in 2021, reflecting a growth of 34.2%[40] - Owner's equity totaled ¥1,672,783,743.76, significantly up from ¥589,633,396.45 in the previous year[42] - The company’s non-current liabilities rose to ¥37,322,949.57 from ¥32,506,145.52, indicating a 14.0% increase year-over-year[40] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥17,686,888.90, a decline of 210.39% due to increased raw material procurement costs[12] - Cash flow from operating activities for the first three quarters of 2022 was ¥214,314,609.50, an increase from ¥151,676,464.57 in 2021[47] - Net cash flow from operating activities was -$17.69 million, a decrease from $16.02 million in the previous period[51] - Total cash inflow from investing activities was $200.90 million, down from $281.06 million year-over-year[51] - Cash outflow from investing activities totaled $340.88 million, compared to $307.25 million in the previous period[51] - Net cash flow from financing activities was $1.08 billion, significantly higher than -$3.70 million in the previous period[53] - The ending balance of cash and cash equivalents was $1.35 billion, up from $432.25 million year-over-year[53] Shareholder Information - The number of shareholders at the end of the reporting period was 28,463, with the largest shareholder holding 34.94% of the shares[23] - The top ten shareholders collectively held 84.06% of the shares, indicating a high concentration of ownership[23] Market and Future Outlook - The increase in revenue was attributed to sustained growth in sales volume[19] - The company plans to continue expanding its market presence and investing in R&D to drive future growth[19] - The company has not disclosed any significant new strategies or market expansions during the reporting period[32] Other Financial Metrics - The company reported a total of ¥2,463,741.72 in non-recurring gains for the period, primarily from government subsidies[13] - The company reported a significant increase in accounts receivable, which rose to CNY 27,115,028.07 from CNY 26,373,531.16, reflecting a growth of about 2.8%[33] - The company has ongoing development expenditures amounting to CNY 65,003,816.96, up from CNY 51,364,267.51, indicating a focus on innovation and product development[37] - The company reported a significant increase in other income, totaling ¥3,220,346.65 in 2022, down from ¥7,388,912.19 in 2021[44] - The impact of exchange rate changes on cash and cash equivalents was $615,654.37, compared to $369,032.30 in the previous period[53]